Table 1.
Summary of three patients who developed second primary uterine malignancy.
| Age (years) | Latency (months) | Histology | Treatment | Survival | |
|---|---|---|---|---|---|
| 1 | 56 | 76 | CS (endometrial stromal sarcoma, rhabdomyosarcoma, clear cell carcinoma, serous carcinoma) | TAH + BSO + LN sampling, Paclitaxel + carboplatin | 20 months, DOD |
| 2 | 80 | 118 | CS (undifferentiated sarcoma, undifferentiated carcinoma) | Best supportive care | 2 months, DOD |
| 3 | 70 | 68 | CS (osteosarcoma, clear cell carcinoma) | Exploratory laparotomy | 4 months, DOD |
CS; carcinosarcoma, TAH; total abdominal hysterectomy, BSO; bilateral salpingo-oophorectomy, LN; lymph node, DOD; dead of disease.